Medicine and Dentistry
Biological Marker
50%
Cancer
50%
Cancer Growth
100%
Clinical Trial
50%
Colon Carcinoma
50%
Colorectal Carcinoma
50%
Disease Free Survival
50%
DNA Topoisomerase (ATP Hydrolysing)
100%
In Vitro
50%
Long Untranslated RNA
100%
Metastatic Carcinoma
100%
Metastatic Colorectal Cancer
100%
RNA Sequencing
50%
Topoisomerase Inhibitor
100%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
50%
Cancer Growth
100%
Clinical Trial
50%
Colon Carcinoma
50%
Colorectal Carcinoma
50%
Disease Free Survival
50%
DNA Topoisomerase (ATP Hydrolysing)
100%
DNA Topoisomerase Inhibitor
100%
Long Untranslated RNA
100%
Metastasis
50%
Metastatic Colorectal Cancer
100%
Transcriptome
50%
Viability Assay
50%
Keyphrases
Aggressive Phenotype
20%
Chromobox Family
20%
Clinical Trials
20%
Colorectal Cancer
20%
Colorectal Cancer Progression
100%
Differentially Expressed mRNAs (DEmRNAs)
20%
Disease-free Survival
20%
FDA-approved Drugs
20%
Gastrointestinal Malignancies
20%
High-throughput
20%
Metastasis
20%
Metastatic Colorectal Cancer (mCRC)
100%
Metastatic Disease
20%
Non-coding RNA (ncRNA)
100%
Primary Colon Cancer
20%
Therapeutic Target
20%
Topoisomerase IIα
40%
Topoisomerase Inhibitors
40%
Transcriptome Sequencing
20%
Treatment Resistance
20%
Viability Assay
20%
Biochemistry, Genetics and Molecular Biology
Clinical Trial
50%
Colon
50%
Disease Free Survival
50%
DNA Gyrase
100%
DNA Topoisomerase
100%
Long Non-Coding RNA
100%
RNA
50%
RNA Sequencing
50%
Topoisomerase
100%